MeSH tree: D03.383.725.050.263
Crizotinib, an approved treatment for advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC), did not improve disease-free survival (DFS) when given as adjuvant therapy in patients with surgically resected early-stage ...
Sep 7, 2025
0
0
A large team of medical researchers and doctors has found via phase III clinical trial that the ALK inhibitor lorlatinib is highly effective for treating non–small cell lung cancer (NSCLC).
A Pfizer lung cancer drug has been shown to greatly reduce tumor progression and improve survival outcomes for people in the advanced stages of a rare form of the disease, according to trial results published Friday.
May 31, 2024
0
0
A new editorial paper titled "Latest updates on MET targeted therapy for EXON 14 mutations in lung cancer" has been published in Oncotarget.
Sep 11, 2023
0
13
Anaplastic large cell lymphoma, a form of non-Hodgkin lymphoma, is the most common aggressive lymphoma in children. Chemotherapy and radiation fail to cure about 30% of cases. When tumors are driven by the oncogene ALK—which ...
Aug 3, 2023
0
22
A University of Kentucky Markey Cancer Center research team identified an existing cancer drug that shows promise as a treatment for the most common type of non-small cell lung cancer.
Jul 19, 2023
0
1
In a significant step for the treatment of neuroblastoma, an international group of researchers led by Children's Hospital of Philadelphia (CHOP), Winship Cancer Institute of Emory University and the New Approaches to Neuroblastoma ...
Apr 3, 2023
0
21
